Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):e339-e343. doi: 10.1016/j.clml.2018.06.003. Epub 2018 Jun 18.

Authors

Kian J Rahbari¹, Jason D Nosrati², Tanya M Spektor³, James R Berenson⁴

Affiliations

¹ James R. Berenson, MD, Inc, West Hollywood, CA.
² Institute for Myeloma and Bone Cancer Research, West Hollywood, CA.
³ Oncotherapeutics, West Hollywood, CA.
⁴ James R. Berenson, MD, Inc, West Hollywood, CA; Institute for Myeloma and Bone Cancer Research, West Hollywood, CA; Oncotherapeutics, West Hollywood, CA. Electronic address: jberenson@imbcr.org.

PMID: 30033209
DOI: 10.1016/j.clml.2018.06.003

No abstract available

Keywords: BCL-2; BCL-2 inhibitor; Daratumumab; Multiple myeloma; Venetoclax.

Publication types

Case Reports

MeSH terms

Aged
Antibodies, Monoclonal / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bortezomib / administration & dosage
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
Dexamethasone / administration & dosage
Female
Humans
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology
Prognosis
Remission Induction
Sulfonamides / administration & dosage

Substances

Antibodies, Monoclonal
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
daratumumab
Bortezomib
Dexamethasone
venetoclax